Compare Johnson & Johnson (JNJ) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Wix.Com Ltd — how do they compare? Johnson & Johnson trades at $249.4 (market cap $598.96B), while Wix.Com Ltd trades at $51.47 (market cap $2.23B). The key difference: Johnson & Johnson is far larger — about 268.6× Wix.Com Ltd's market cap, and Johnson & Johnson pays a 2.15% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals.
| JNJ | WIX | |
|---|---|---|
Market Cap | $598.96B | $2.23B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $184.24 |
52-Week Low | $164.36 | $40.43 |
Enterprise Value | $631.90B | $1.80B |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Wix trades at $53.34, up 3.67% on the day, with a bearish technical signal and mixed fundamentals. Revenue grew to $1.99B in 2025, but net income fell to $50.65M with a negative margin of -1.97%. The stock faces headwinds from recent earnings misses and legal investigations, yet maintains strong analyst support with a consensus price target of $83.07.
The outlook is cautious due to high valuation multiples and operational risks, but long-term growth potential exists if Wix can leverage AI tools and partnerships to improve profitability. Key risks include competitive pressure and ongoing legal scrutiny, while institutional sentiment remains predominantly bullish.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
